NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.
about
"Stormy waters ahead": global emergence of carbapenemasesKinetics of avibactam inhibition against Class A, C, and D β-lactamasesEmergence of Klebsiella pneumoniae carbapenemase-producing bacteriaThree decades of beta-lactamase inhibitorsNXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosisAn Automated Miniaturized Method to Perform and Analyze Antimicrobial Drug Synergy AssaysNew β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Substituted aryl malonamates as new serine beta-lactamase substrates: structure-activity studiesReclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Antibiotic discovery in the twenty-first century: current trends and future perspectives.In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Investigational antimicrobial agents of 2013.Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniaeActivity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.Structure-based approach for identification of novel phenylboronic acids as serine-β-lactamase inhibitors.Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjectsEfficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection modelTackling antibiotic resistance: a dose of common antisense?Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system.New β-lactam antibiotics and β-lactamase inhibitors.Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104.Status report on carbapenemases: challenges and prospects.Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns.OXA-48-like carbapenemases: the phantom menace.Ceftazidime for respiratory infections.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam.Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
P2860
Q21131125-90E52712-B90D-46FB-ADCA-9D76F359169DQ24617763-67C70F20-1788-4E33-A41F-832BDCC2C0FFQ24618178-0134CD6B-8609-440E-B3B1-9D85A1DFB7CEQ24646623-9E367D11-2F4E-432C-8F31-B0D7A5E29477Q27679097-BA286F5F-C3BB-4D56-987A-5C14E9810B3EQ30364361-F47CE200-A137-4C74-9258-0C13BB746CB6Q33622976-7F607B90-E5C7-485D-AB36-D5808BC7B770Q33638319-9300F8F7-3F54-422A-BA7C-26B7AE649F36Q34058217-893EF184-EFDA-4EFE-97C7-3FB24EFF9579Q34121033-943A886D-B689-45A6-B9B2-DD62DE17FF44Q34134689-0FA564BE-8400-4AC2-9D8C-F80A5D792405Q34325573-D68DD5D5-1ED4-45B2-B6FF-89E5F69D8E06Q34375204-F8D09A93-D0EF-472C-A7CA-7A2FFAED4673Q34483491-FFADE487-2797-4D63-901E-FC0832AB8AD7Q34932937-2F35E9B1-94F2-415F-A6B7-0FE7B9A3C8D4Q35065798-F8EE9C20-4C06-4D70-89A8-C7ADA7709079Q36134510-DC670A16-FA7F-4A2A-B819-BBFFB9A23E05Q36571851-4FB34112-8FFA-4E31-ACAB-DAA4B02117B5Q36667104-929472FE-5F4E-4F32-98B1-0FDB17D89504Q36915096-6C964AE0-91B1-4A93-BA5D-2C2C8CD787B1Q36969982-C5A6AACD-ED74-4384-A502-ABC954F1065DQ37263439-22A624E8-C961-436F-8DB0-2CB652DE2E92Q37323966-B8B2D345-3EFF-47D6-9012-DBF6680FA396Q37383945-938E2807-7262-4F61-8863-AF8E33E80F65Q37788685-304327AB-DB1B-4847-B37A-1E1BCE20C81DQ37845845-334C7A7C-115B-41EE-844E-ECC37069799FQ37879199-B9D6BFB2-1EBD-47B6-A6E2-D5D97BC6DCC4Q38001333-2634411C-45AE-4275-A9C6-3A9CD7797515Q38002399-BC42EC4E-F205-455E-9C67-DAE251C387BFQ38040144-D47F6B60-291E-447B-AD99-2B23435A8C91Q38130715-16BBA41E-08B0-4B13-AC6D-480ACA220B97Q38595451-5C34988D-1E28-446C-A9FD-1FC91C7A2F57Q38740494-3ACDAB20-414C-47CA-85CC-D630C5A00E87Q38797485-CCC76D57-BFC5-43A8-A437-7E58488A08ADQ38850240-CD821E48-2D01-4656-B7EF-F78DA71BF2E0Q38985065-11AE1668-181F-433C-9FA0-FD270C7464CDQ40389902-D23AA3FE-E7CA-4C0F-8B5D-7DFCA2EC7215Q40617746-68C7E165-9C6D-400F-A213-A93948951A67Q40702364-241DCBDB-2453-45B0-AF63-23E2F0B6474CQ40945550-D8600157-36D8-4E66-A01F-03ED69D7DC00
P2860
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
NXL104 combinations versus Ent ...... lactamases and carbapenemases.
@en
NXL104 combinations versus Ent ...... lactamases and carbapenemases.
@nl
type
label
NXL104 combinations versus Ent ...... lactamases and carbapenemases.
@en
NXL104 combinations versus Ent ...... lactamases and carbapenemases.
@nl
prefLabel
NXL104 combinations versus Ent ...... lactamases and carbapenemases.
@en
NXL104 combinations versus Ent ...... lactamases and carbapenemases.
@nl
P2093
P356
P1476
NXL104 combinations versus Ent ...... lactamases and carbapenemases.
@en
P2093
Christine Miossec
David M Livermore
Marina Warner
Shazad Mushtaq
P304
P356
10.1093/JAC/DKN320
P407
P577
2008-08-09T00:00:00Z